RHYTHM PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $188.66M.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $32.11M.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $48.88M, a 58.22% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $116.97M.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $48.88M, a 62.72% decline from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $131.11M, a 18.93% decline from fiscal 2021.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2021 was $161.73M.
- RHYTHM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2019 was $161.35M, a 0.94% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $188.66M 10-Q · filed 2025-11-04 | |
| 2025-03-31 | $32.11M 10-Q · filed 2026-08-04 | |
| 2023-12-31 | $48.88M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $48.88M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $131.11M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $116.97M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $161.73M 10-K · filed 2024-02-29 | |
| 2021-03-31 | $161.73M 10-Q · filed 2022-11-08 | |
| 2019-12-31 | $161.35M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $162.88M 10-K · filed 2020-03-02 | |
| 2018-06-30 | $163.03M 10-Q · filed 2019-11-01 | |
| 2017-12-31 | $125.66M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |